Delcath Systems Revenue and Competitors
Estimated Revenue & Valuation
- Delcath Systems's estimated annual revenue is currently $7.5M per year.
- Delcath Systems's estimated revenue per employee is $101,351
- Delcath Systems's total funding is $138.4M.
Employee Data
- Delcath Systems has 74 Employees.
- Delcath Systems grew their employee count by 37% last year.
Delcath Systems's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Assoc. VP Clinical Operations at Delcath Systems, Inc. | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Sr VP Clinical Development & Medical Affairs | Reveal Email/Phone |
4 | CEO | Reveal Email/Phone |
5 | General Counsel, Corporate Secretary and Chief Compliance Officer | Reveal Email/Phone |
6 | SVP Finance | Reveal Email/Phone |
7 | VP Finance | Reveal Email/Phone |
8 | VP, General Manager Interventional Oncology | Reveal Email/Phone |
9 | Associate Director, Contracts Administration | Reveal Email/Phone |
10 | Senior Director, Marketing | Reveal Email/Phone |
Delcath Systems Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Delcath Systems?
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe
keywords:N/A
$138.4M
Total Funding
74
Number of Employees
$7.5M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Delcath Systems News
Delcath Systems, Inc. (NASDAQ:DCTH) Insider Gerard J. Michel Buys 2,000 Shares. Posted by admin on Apr 19th, 2022.
They set a sell rating on the stock. 4/11/2022 Delcath Systems had its price target lowered by analysts at Canaccord Genuity Group Inc. from...
NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the...
Delcath Systems, Inc. announced that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional details concerning the debt facility will be contained in the company' ...
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.7M | 74 | -14% | N/A |
#2 | $16.7M | 74 | -7% | N/A |
#3 | $9M | 74 | 17% | $12.4M |
#4 | $15.2M | 74 | 7% | N/A |
#5 | $10M | 74 | -7% | N/A |